| Literature DB >> 34565149 |
Matthew R Balmforth1, Jessica Haigh1, Vajinder Kumar2,3, Wenyue Dai2, Christian Tiede4, Darren C Tomlinson4, Jim Deuchars5, Michael E Webb2, W Bruce Turnbull2.
Abstract
A significant unmet need exists for the delivery of biologic drugs such as polypeptides or nucleic acids to the central nervous system for the treatment and understanding of neurodegenerative diseases. Naturally occurring bacterial toxins have been considered as tools to meet this need. However, due to the complexity of tethering macromolecular drugs to toxins and the inherent dangers of working with large quantities of recombinant toxins, no such route has been successfully exploited. Developing a method where a bacterial toxin's nontoxic targeting subunit can be assembled with a drug immediately prior to in vivo administration has the potential to circumvent some of these issues. Using a phage-display screen, we identified two antibody mimetics, anticholera toxin Affimer (ACTA)-A2 and ACTA-C6 that noncovalently associate with the nonbinding face of the cholera toxin B-subunit. In a first step toward the development of a nonviral motor neuron drug-delivery vehicle, we show that Affimers can be selectively delivered to motor neurons in vivo.Entities:
Mesh:
Substances:
Year: 2021 PMID: 34565149 DOI: 10.1021/acs.bioconjchem.1c00373
Source DB: PubMed Journal: Bioconjug Chem ISSN: 1043-1802 Impact factor: 4.774